Phase III Cat-PAD Study

PHASE3CompletedINTERVENTIONAL
Enrollment

1,408

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2016

Conditions
Rhinoconjunctivitis
Interventions
DRUG

Cat-PAD

1 dose every 4 weeks

DRUG

Placebo

1 dose every 4 weeks

Trial Locations (118)

Unknown

Rolling Hills Estates

Colorado Springs

Denver

Wheat Ridge

Eagle

Meridian

Chicago

Evanston

Forrest

Normal

Iowa City

Overland Park

Bangor

Brockton

Ypsilanti

Minneapolis

Kansas City

St Louis

Bozeman

Missoula

Bellevue

Fremont

Omaha

Ocean Township

Albuquerque

Corning

Newburgh

Fargo

Minot

Canton

Cincinnati

Middleburg Heights

Sylvania

Toledo

Tulsa

Lake Oswego

Medford

Portland

Blue Bell

Pittsburgh

Germantown

Nashville

Dallas

San Antonio

Draper

Glen Allen

South Burlington

Warrenton

Spokane

Greenfield

Madison

Milwaukee

Brussels

Ghent

Leuven

Burlington

Corruna

Hamilton

Kanata

London

Newmarket

Niagara Falls

Oshawa

Ottawa

Toronto

Montreal

Pointe-Claire

Québec

Trois-Rivières

Brnho

Čáslav

České Budějovice

Jablonec nad Nisou

Kutná Hora

Prague

Rychnov nad Kněžnou

Berlin

Bonn

Bramsche

Cologne

Hamburg

Heidelberg

Mönchengladbach

München

Münster

Neuss

Osnabrück

Wesel

Wiesbaden

Wuppertal

Budapest

Csorna

Pécs

Tatabánya

Bydgoszcz

Gdansk

Katowice

Krakow

Lodz

Lublin

Poznan

Rzeszów

Tarnów

Warsaw

Wroclaw

Zabrze

Zawadzkie

Barnaul

Moscow

Novosibirsk

Omsk

Saint Petersburg

Stavropol

Tomsk

Yekaterinburg

Bardejov

Martin

Poprad

All Listed Sponsors
collaborator

inVentiv Health Clinical

OTHER

collaborator

Pharm-Olam International

INDUSTRY

lead

Circassia Limited

INDUSTRY